FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD)

Source: FDA.gov

Note: If you have any questions about the laws governing the sales of CBD Products, contact your State Pharmacy Board.

Consumer Information

• What You Should Know About Using Cannabis, Including CBD, When Pregnant or Breastfeeding
• What You Need to Know (And What We’re Working to Find Out) About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD

FDA Communications

• FDA warns 15 companies for illegally selling various products containing cannabidiol as agency details safety concerns
• Remarks at the Council for Responsible Nutrition Conference
• Remarks at the National Industrial Hemp Council 2019 Hemp Business Summit
• FDA, FTC warn company marketing unapproved cannabidiol products with unsubstantiated claims to treat teething and ear pain in infants, autism, ADHD, Parkinson’s and Alzheimer’s disease
• Congressional Testimony: Hemp Production and the 2018 Farm Bill
  • Archived Video
• FDA is Committed to Sound, Science-based Policy on CBD
• Remarks at the FDA Public Hearing on Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds
• Statement on new steps to advance agency’s continued evaluation of potential regulatory pathways for cannabis-containing and cannabis-derived products
• Statement on signing of the Agriculture Improvement Act and the agency’s regulation of products containing cannabis and cannabis-derived compounds
• Statement on the importance of conducting proper research to prove safe and effective medical uses for the active chemicals in marijuana and its components
• FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy

Regulatory Resources

• FDA and Cannabis: Research and Drug Approval Process
• Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds; Public Hearing
  • Federal Register Notice
  • Public Hearing Page
  • Public Docket
• Warning Letters and Test Results for Cannabidiol-Related Products
• State, Local, Tribal, Territorial (SLTT) Regulatory Officials: FDA is committed to working with our SLTT public health regulatory partners as developments occur in the regulatory landscape. Please contact the Intergovernmental Affairs team with any questions at IGA@fda.hhs.gov.